
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
The Virtual Rare Disease Specialist Contract (VRDS) supports Mirum’s bile acid portfolio, including CHOLBAM and CTEXLI, and is responsible for expanding healthcare professional (HCP) engagement, generating and nurturing qualified leads, and supporting patient identification opportunities.
Working as an extension of the field sales organization, the VRDS conducts approximately 80% of work virtually and travels within the United States approximately 20% of the time. The VRDS will proactively engage targeted HCPs, identify new business opportunities, and maintain consistent follow-up with existing leads to support appropriate patient identification and treatment initiation. The individual will work closely with Regional Account Managers (RAMs), Marketing, and other cross-functional partners to coordinate outreach, prioritize opportunities, and ensure seamless customer engagement.
The VRDS will be responsible for managing virtual engagement activities within an assigned geographic region (East or West), developing relationships with targeted specialists, and executing approved promotional initiatives. Responsibilities will include proactive lead generation for CHOLBAM, lead nurturing, conference coverage, and follow-up on marketing-generated and genetic testing-related HCP opportunities for CTEXLI. With other responsibilities as assigned.
The successful candidate will be a proactive, results-oriented professional with strong communication skills, clinical curiosity, and the ability to independently identify and advance opportunities. The ideal candidate thrives in a fast-paced, collaborative environment and demonstrates an entrepreneurial mindset, strong organizational skills, and a commitment to improving outcomes for patients living with rare diseases. The initial contract term is 12 months, with potential to extend based on business needs, performance, and the governing agreement.
This opportunity is ideal for an ambitious, early-career professional looking to develop their sales capabilities within the pharmaceutical industry. We are seeking a highly motivated, resourceful, and coachable individual who thrives on building relationships, pursuing opportunities, and delivering measurable results. Prior pharmaceutical experience is not required; initiative, persistence, and a strong work ethic are essential.
The VRDS will be accountable for achieving established objectives related to lead generation, lead nurturing, HCP engagement, and field collaboration.
Performance measures may include:
Specific activity, verification, meeting-setting, and conference-support targets will be defined in writing based on regional opportunity and business priorities. The $15,000 performance bonus is contingent on achievement of separately documented performance criteria, measurement period, and payment terms; it is not guaranteed.
Training: Standard RAM training process and required compliance onboarding.
Reporting: Designated Area Business Director.
Contract timeline: Initial 12-month engagement, with potential to extend based on business needs and performance.
Systems/resources: Authorized Veeva reporting access, Komodo leads, Power BI access, and approved marketing resources, including ready-to-execute (RTE) materials.
The initial contract term will be 12 months, with the potential for extension based on business needs and performance.
Either party may terminate the engagement prior to the end of the contract term, subject to the following written notice requirements:
#LI-REMOTE
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.